Clinical Trial Update: Dalteparin in Preventing Blood Clots in Patients With Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update on using dalteparin to prevent blood clots in patients with lung cancer; current status is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Venous Thromboembolism

Drugs mentioned

• Dalteparin (dalteparin)

Snippet

Sponsor: Velindre NHS Trust | Conditions: Lung Cancer, Thromboembolism | Phase 3 | Status: UNKNOWN